MASM
IONS icon

MH & Associates Securities Management’s Ionis Pharmaceuticals IONS Stock Holding History

MH & Associates Securities Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.9K Hold
200
– – 0.01% 69
2026
Q1 		$15K Hold
200
– – 0.01% 69
2025
Q4 		$15.8K Buy
+200
New +$15.1K 0.01% 71

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

MH & Associates Securities Management's IONS Position: Q2 2026 in Review

MH & Associates Securities Management held its Ionis Pharmaceuticals (IONS) position steady in Q2 2026 at 200 shares worth $15.9K. The position accounts for 0.01% of the portfolio, ranked #69.

MH & Associates Securities Management first reported a position in IONS in Q4 2025 and has held it in 3 quarters since. 515 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • MH & Associates Securities Management held 200 shares of Ionis Pharmaceuticals worth $15.9K as of Q2 2026.
  • MH & Associates Securities Management left its Ionis Pharmaceuticals share count unchanged in Q2 2026.
  • Ionis Pharmaceuticals made up 0.01% of MH & Associates Securities Management's portfolio in Q2 2026, its #69 holding.
  • MH & Associates Securities Management first reported a position in Ionis Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 515 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on MH & Associates Securities Management's 13F filing for Q2 2026, filed 28 Jul 2026.